Search results for "Highlights"


 
Results 41 - 50 of about 261 for "Highlights".

3 actions may help reluctant patients begin insulin therapy for type 2 diabetes

Patients' perceived helpfulness of certain actions by health care professionals was linked to earlier insulin initiation and greater insulin continuation over time, a survey found.
February 2019

Drug-eluting stents may not confer advantage in diabetic patients

probably indicates a more accelerated intimal hyperplasia, greater degree of vascular inflammation and/or endothelial dysfunction, and increased plaque vulnerability in insulin-treated diabetic patients, and highlights the need for
January 2019

Weekly GLP-1 analogue associated with reduced MI, stroke risk, industry study finds

The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.
October 2016

Cardiovascular event rates similar among newer second-line medications for type 2 diabetes

The comparison of dipeptidyl peptidase-4 inhibitors with other drug classes did find higher rates of major adverse cardiovascular events with basal insulin, sulfonylureas, and meglitinides than with the newer drugs.
January 2019

Liraglutide may offer high-risk patients protection from CV events, death, study finds

The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was funded by Novo Nordisk and the National Institutes of Health, randomized 9,340 patients ages 50 years and older to 1.8 mg of
July 2016

SGLT2 inhibitors associated with increased risk of amputations, diabetic ketoacidosis

Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists had similar rates of other adverse events, including bone fracture, acute kidney injury, serious urinary tract infection, venous thromboembolism, and
December 2018

New equation with five variables helps predict hip fracture risk in type 2 diabetes

Age, sex, body mass index, peripheral sensory neuropathy, and estimated glomerular filtration rate were the included variables.
December 2018

Highlights

The Endocrine Society recently updated its guidance on primary prevention of atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes in those at metabolic risk.
August 2019

Incretin-based drugs not associated with any increase in risk for pancreatic diseases

The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
November 2018

Spotlight on depression in diabetes

The results highlight the importance of psychosocial interventions for at-risk patients, they concluded.
November 2018

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next